Enliven Therapeutics, Inc.

NASDAQ:ELVN

Biotechnology

Healthcare
$46.41 -0.27%

-$0.12 today

Market cap
$3.42B
Beta
0.40
P/E (TTM)
-28.4
EPS (TTM)
-$1.57
52W Low $14.79High $48.53

Volume 0.99M

Average 1.35M

Returns on capital

Enliven Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-22.6%

avg 1.6%

ROIC

-26.0%

avg -49.4%

ROA

-21.8%

avg -42.3%

Analysis

ROA is currently the strongest return metric at -21.8% versus its period average of -42.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Samuel S. Kintz

Co-Founder & Head of PipelineUSD 956.09K40——

Helen Louise Collins

Chief Medical OfficerUSD 726.42K6325.00K0.04%

Joseph Lyssikatos

Co-Founder & Research FellowUSD 709.4K61——

Richard A. Fair

CEO, President & DirectorUSD 672.66K570<0.01%

Benjamin Hohl

Chief Financial Officer & Head of Corporate DevelopmentUSD 667.89K3738.00K0.06%

Damiette Smit

Vice President of Clinical Development————

Anish Patel

Co-Founder & Chief Operating Officer—4520.00K0.03%

Galya D. Blachman

Chief Legal Officer & Head of Business Development—49——

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 19, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

71

$76.19M

Net Transaction Value

−$76.19M

Net selling

Most Active

Collins Helen Louise

25 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Oct 19, 26

Hohl Benjamin

Direct

Sell$231.5K
Oct 19, 26

Collins Helen Louise

Direct

Sell$192.3K
Oct 1, 26

Garland J. Scott

Direct

Sell$606.7K
Sep 17, 26

Hohl Benjamin

Direct

Sell$176.9K
Sep 17, 26

Hohl Benjamin

Direct

Sell$111.3K
Sep 17, 26

Hohl Benjamin

Direct

Sell$14.9K
Sep 17, 26

Collins Helen Louise

Direct

Sell$145.9K
Sep 17, 26

Collins Helen Louise

Direct

Sell$93.5K
Sep 17, 26

Collins Helen Louise

Direct

Sell$12.4K
Aug 17, 26

Hohl Benjamin

Direct

Sell$270.2K

1–10 of 71

Summary

Insiders reported 0 buys worth $0.00 and 71 sells worth $76.19M over the last 12 months. That adds up to net selling of $76.19M. Collins Helen Louise was the most active insider with 25 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A4 analysts
RevenueN/AN/AN/A
N/A5 analysts
Net IncomeN/AN/AN/A
N/A5 analysts
EBITN/AN/AN/A
N/A5 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Enliven Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about ELVN's management, answered from reported figures.

Who manages ELVN?

Enliven Therapeutics, Inc. (ELVN) lists 8 active executives. The top listed executive is Damiette Smit, Vice President of Clinical Development.

Are ELVN insiders buying or selling?

Recent insider activity shows net selling of $44.40M.